Skip to content

Passive Calf Stretching Therapy in Peripheral Artery Disease

To Stretch, Not Strain: Impact of Passive Stretching on Calf Muscle and Gait Mechanics in PAD

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06041880
Enrollment
24
Registered
2023-09-18
Start date
2024-04-01
Completion date
2027-07-31
Last updated
2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Claudication, Intermittent, Peripheral Artery Disease

Keywords

Endothelial dysfunction

Brief summary

The goal of this clinical trial is to assess the effects of passive calf muscle stretching in patients diagnosed with peripheral artery disease (PAD). The main question it aims to answer are: 1. To determine if daily calf muscle stretching at home improves calf muscle and vascular health. 2. To determine if daily calf muscle stretching at home improves walking performance. Participants will use inflatable ankle splints for 30 minutes a day, 5 days a week for 4-weeks on both days and 4-weeks of no stretching.

Detailed description

Patients with peripheral artery disease will passively stretch their calf muscles using a stretch device on both feet for 30 minutes a day for 4 weeks. Blood vessel health and size, length and function of the calf muscles and tendons and walking performance will be measured. Joint and foot movements as well as calf muscle oxygen levels will be measured during walking performance tests.

Interventions

DEVICEPassive calf muscle stretching device

Modified night splints will be used to passive stretch the calf muscle.

Sponsors

American Heart Association
CollaboratorOTHER
Penn State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Masking description

Due to the nature of the intervention, participants will not be blinded to stretching vs no-stretching interventions. The study team will be blinded to intervention order when performing data analysis.

Intervention model description

Participants will be randomized to 4-weeks of stretching or no stretching. Following the first 4-week intervention, participants will crossover and perform whichever intervention they did not receive previously.

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Presence of PAD * Stable condition (PAD symptoms) for at least 3 months * Age 40-85 * Men and women who are not pregnant or nursing

Exclusion criteria

* Ischemic leg pain at rest; critical limb ischemia (ulceration or gangrene) * Any condition other than PAD that limits the ability to walk * Major surgery or lower extremity revascularization surgery in the past 6 months * Myocardial infarction within past 6 months or unstable angina * Severe lung disease (on supplemental oxygen or frequently use rescue inhalers) * Participants with non-compressible vessels (ABI \> 1.40) * Habitual exercise (30 minutes of continuous activity on 3 or more days per week) * Current tobacco smoker or use of nicotine-containing products * Pregnant or nursing women * History or ankle reconstruction or surgery Recent history (\<1 year) of injuries to the ankle, Achilles tendon, or feet * History of rheumatoid arthritis or other degenerative joint disease * Major medical illness treatment during the prior 12 months * Uncontrolled hypertension * Uncontrolled diabetes * Inability to walk on a treadmill at a slow pace (1.0 mile/hour)

Design outcomes

Primary

MeasureTime frameDescription
6-minute walk test distance6-12 minutesSubmaximal exercise test used to assess aerobic capacity and endurance
Muscle to tendon ratio45 minutesThe ratio of gastrocnemius muscle fascicle length to Achilles' tendon length will be measured using ultrasound
Endothelial function30 minutesPopliteal flow-mediated dilation will be measured as a index of macrovascular endothelial function in the leg.

Countries

United States

Contacts

Primary ContactDavid N Proctor, Ph.D.
dnp3@psu.edu814-571-5234
Backup ContactJocelyn M Delgado, B.S.
jmd956@psu.edu408-679-8390

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026